cui1,cui2,relation,name1,name2,type1,type2,weight,predicate
C0003234,C1516170,DISRUPTS,Anthracycline Antibiotics,Cancer Cell Growth,antb,neop,1,DISRUPTS_ANTBdrptNEOP
C0011015,C0027651,DISRUPTS,daunorubicin,Neoplasms,antb,neop,1,DISRUPTS_ANTBdrptNEOP
C0013089,C0027651,DISRUPTS,doxorubicin,Neoplasms,antb,neop,1,DISRUPTS_ANTBdrptNEOP
C0013089,C0598934,DISRUPTS,doxorubicin,tumor growth,antb,neop,3,DISRUPTS_ANTBdrptNEOP
C0013089,C1516170,DISRUPTS,doxorubicin,Cancer Cell Growth,antb,neop,1,DISRUPTS_ANTBdrptNEOP
C0013089,C2939419,DISRUPTS,doxorubicin,Secondary Neoplasm,antb,neop,1,DISRUPTS_ANTBdrptNEOP
C0013089,C4722524,DISRUPTS,doxorubicin,Blood Vessel Tumors,antb,neop,1,DISRUPTS_ANTBdrptNEOP
C0072980,C1516170,DISRUPTS,sirolimus,Cancer Cell Growth,antb,neop,1,DISRUPTS_ANTBdrptNEOP
C0717668,C0027651,DISRUPTS,daunorubicin liposomal,Neoplasms,antb,neop,1,DISRUPTS_ANTBdrptNEOP
